KPMG
12.5.2021 03:51:10 CEST | Business Wire | Press release
Ogletree Deakins and KPMG Law in Germany1 are forming a global alliance to provide businesses with global workforce solutions. This alliance will be instrumental in expanding immigration and employment law reach for both organizations and will enable KPMG firms outside of the US2 to bring the US capability and services of Ogletree Deakins to their clients around the world.
The alliance is in response to growing client demand for a technology-powered, globally unified approach to business challenges faced in the areas of immigration and global mobility, labor and employment, and the associated tax, compensation, and benefits issues. This non-exclusive alliance with Ogletree Deakins does not include KPMG in the US or entities that it owns or controls, which do not provide legal services3 .
“As businesses expand and look to shore up recovery in the post-pandemic world, there is increasing pressure for multinational organizations seeking to get the right people in the right places at the right time, and in compliance with the requirements of any given jurisdiction,” said Thomas Wolf , Head of Global Immigration Services for the KPMG organization. “Ogletree Deakins’ labor, employment and immigration experience in the United States is a perfect fit for KPMG’s organization of firms as we expand our global legal services practice4 and our global mobility services offerings around the world. We are excited to join forces with Ogletree Deakins to offer clients even deeper global coverage for their pressing employment and immigration legal matters.”
Both Ogletree Deakins and KPMG Law in Germany are leaders in utilizing technology and innovation to enhance client service, including in the areas of artificial intelligence, data analytics and knowledge management. By combining the strengths of both organizations, this new alliance will provide clients with an increased breadth of technology solutions. KPMG Law in Germany is part of the broader KPMG Law / Global Legal Services network across KPMG firms, with 2,800 lawyers in 81 jurisdictions.
“Ogletree Deakins is an international labor and employment firm and has established an extensive network of lawyers practicing in 53 offices across North America and in Europe to meet our clients’ needs. Our alliance with KPMG Law in Germany will benefit clients by complementing our US labor, employment and immigration offerings with ‘end-to-end’ workplace solutions—including tax, compensation, global immigration, and related advisory and consulting services, over a truly global footprint. Our firm shares a vision with the KPMG network for client service, innovation and cutting-edge technology solutions, and we are already working together on a next generation mobility services platform,” said Matt Keen , managing shareholder of Ogletree Deakins.
About Ogletree Deakins
Ogletree Deakins is one of the largest US labor and employment law firms representing management in all types of employment-related legal matters. Premier client service, as outlined in the firm’s Client Pledge, is one of the firm’s top priorities and a cornerstone of its core values. U.S. News – Best Lawyers® “Best Law Firms” has named Ogletree Deakins a “Law Firm of the Year” for 10 consecutive years. In 2021, the publication named Ogletree Deakins its “Law Firm of the Year” in the Litigation – Labor & Employment category. Ogletree Deakins has more than 900 attorneys located in 53 offices across the United States and in Europe, Canada, and Mexico. The firm represents a diverse range of clients, from small businesses to Fortune 50 companies. More: ogletree.com.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 146 countries and territories and in FY20 had close to 227,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. More: kpmg.com
_______________________________
1 The agreement will be initially signed by KPMG Law Rechtsanwaltsgesellschaft mbH (“KPMG Law in Germany”), which is associated with KPMG AG Wirtschaftsprüfungsgesellschaft, the German member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. Other non-US member firms are expected to join this non-exclusive alliance over the next several months.
2 KPMG Law in Germany was established in 2007 and is an independent corporate law firm associated with KPMG AG Wirtschaftsprüfungsgesellschaft and affiliated with the KPMG International Cooperative. This non-exclusive alliance with Ogletree Deakins does not include the KPMG US member firm or entities that it owns, or controls, which do not provide legal services. For cases where KPMG in the US clients require immigration and/or employment and labor law services, Ogletree Deakins may contract with these clients separately.
3 For cases where KPMG US clients require immigration and/or employment and labor law services, Ogletree Deakins would contract with these clients separately.
4 Certain member firms of the KPMG global organization, including KPMG in the US, do not provide legal services. For the purpose of this press release any commentary will be on general concepts only and is not in any way intended as legal advice or views on laws of any jurisdiction.
Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates and related entities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210509005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom